NuCana (NASDAQ:NCNA) Issues Quarterly Earnings Results

NuCana (NASDAQ:NCNA) announced its quarterly earnings data on Thursday. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.65) by $2.18, Zacks reports.

NuCana Stock Down 1.0%

NASDAQ:NCNA traded down $0.01 during mid-day trading on Thursday, hitting $0.93. The stock had a trading volume of 26,467 shares, compared to its average volume of 27,888. The stock has a 50-day simple moving average of $1.14 and a two-hundred day simple moving average of $1.66. NuCana has a twelve month low of $0.88 and a twelve month high of $4.55.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a research note on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, NuCana currently has an average rating of “Sell”.

NuCana Company Profile

NuCana plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company uses its ProTide technology to create nucleotide analog medicines designed to improve the delivery and activity of existing chemotherapy agents while addressing mechanisms that can limit treatment effectiveness. NuCana’s development portfolio has included NUC-1031, also known as Acelarin, a ProTide form of gemcitabine evaluated in several solid tumors. The company has also advanced NUC-3373, a ProTide-based fluoropyrimidine designed to deliver the active component of 5-fluorouracil, and NUC-7738, an investigational cancer therapy based on a nucleoside analog.